Effect of combined CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome in breast cancer indicates endogenous and exogenous interplay

被引：0
|
作者：
Xie, H. [1 ]
Lovrot, J. [1 ]
Lindh, J. D. [2 ]
Bergh, J. [1 ]
Sim, S. [3 ]
机构：
[1] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept Clin Pharmacol, Stockholm, Sweden
[3] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9P
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [1] Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay
    Sim, Sarah
    Lovrot, John
    Lindh, Jonatan D.
    Bergh, Jonas
    Xie, Hanjing
    PHARMACOGENOMICS, 2018, 19 (13) : 1027 - 1037
  • [2] Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
    Schroth, Werner
    Antoniadou, Lydia
    Fritz, Peter
    Schwab, Matthias
    Muerdter, Thomas
    Zanger, Ulrich M.
    Simon, Wolfgang
    Eichelbaum, Michel
    Brauch, Hiltrud
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5187 - 5193
  • [3] CYP2C19 in addition to CYP2D6 influences tamoxifen efficacy in advanced breast cancer
    Bolbrinker, J.
    Karle, J.
    Vogl, S.
    Eucker, J.
    Wischnewsky, M.
    Regierer, A. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 188 - 188
  • [4] The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients
    van Schaik, Ron H. N.
    Kok, Marleen
    Sweep, Fred C. G. J.
    van Vliet, Martin
    van Fessem, Marianne
    Meijer-van Gelder, Marion E.
    Seynaeve, Caroline
    Lindemans, Jan
    Wesseling, Jelle
    van't Veer, Laura J.
    Span, Paul N.
    van Laarhoven, Hanneke
    Sleijfer, Stefan
    Foekens, John A.
    Linn, Sabine C.
    Berns, Els M. J. J.
    PHARMACOGENOMICS, 2011, 12 (08) : 1137 - 1146
  • [5] Impact of CYP2C19 and CYP2D6 Genotype on Escitalopram, Risperidone, and Aripiprazole Treatment
    Jukic, Marin
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 24 - 25
  • [6] Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity Role of CYP2D6 and CYP2C19 in longevityRole of CYP2D6 and CYP2C19 in longevity
    L. Bathum
    K. Andersen-Ranberg
    J. Boldsen
    K. Brøsen
    B. Jeune
    European Journal of Clinical Pharmacology, 1998, 54 : 427 - 430
  • [7] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
  • [8] An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19
    Tamminga, WJ
    Wemer, J
    Oosterhuis, B
    Brakenhoff, JPG
    Gerrits, MGF
    de Zeeuw, RA
    de Leij, LFMH
    Jonkman, JHG
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (02) : 143 - 146
  • [9] An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19
    Wim J. Tamminga
    Johan Wemer
    Berend Oosterhuis
    Jan P. Brakenhoff
    Mireille G. Gerrits
    Rokus A. de Zeeuw
    Lou F. de Leij
    Jan H. Jonkman
    European Journal of Clinical Pharmacology, 2001, 57 : 143 - 146
  • [10] Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
    Lim, Joanne S. L.
    Chen, Xiang A.
    Singh, Onkar
    Yap, Yoon S.
    Ng, Raymond C. H.
    Wong, Nan S.
    Wong, Mabel
    Lee, Edmund J. D.
    Chowbay, Balram
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (05) : 737 - 750
12345